Updated:
Zion Ventures
Zion Ventures is a 2023-founded fund-of-funds manager focused on cannabis and plant medicine, blending primary commitments, secondaries, and...
Zion Ventures
Zion Ventures was established in 2023, emerging at a time when institutional capital was still structurally scarce for plant-touching businesses in the United States. The firm operates from Dover, Delaware, and was purpose-built to provide allocators with diversified exposure to the cannabis and industrial hemp value chain through a multi-manager framework. Rather than making single-company bets, Zion aggregates commitments to external venture and growth equity managers, supplementing those fund positions with direct co-investments and secondary acquisitions. The firm's strategy spans the full lifecycle of cannabis-adjacent companies: seed-stage startups developing cultivation technology, early-stage operators building retail and distribution platforms, and late-stage enterprises executing buy-and-build strategies in fragmented state markets. Its capital reaches beyond cultivation and retail into industrial hemp processing, plant-based medicine, and pharmaceutical R&D tied to cannabinoids. Zion pursues opportunities across the United States and globally, navigating the patchwork of state legalization while maintaining flexibility to back managers in international jurisdictions where medical and recreational cannabis frameworks have matured, including Canada and Europe. The vehicle's structure allows it to deploy across primary fund commitments, direct investments into mid-stage companies, and secondary purchases of limited-partner interests — giving the firm a toolkit that adjusts to liquidity and valuation dislocations. Zion Ventures maintains a small, focused team typical of a newly formed fund-of-funds manager, operating without additional regional offices. Zion's structural differentiator rests on its exclusive focus on plant medicine within a fund-of-funds architecture. Most cannabis investors operate single-family or venture capital structures that select individual companies; Zion instead invests in the managers themselves, creating a curated, risk-distributed portal into an asset class where traditional institutional gatekeepers remain sidelined by federal illegality. This intermediary model positions Zion as a specialist allocator for endowments and family offices that cannot direct-invest in cannabis but seek exposure through vetted general partners.
General information
Firm type
Private Equity
Year founded
2023
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Dover
Corporate office
Dover, DE, United States
Sector focus
Frequently asked questions
How does Zion Ventures invest in an industry that remains federally illegal in the United States?
Zion Ventures invests through fund commitments and co-investments in companies that operate in compliance with state-level cannabis laws. The firm does not directly touch the cannabis plant; it invests in managers and operating companies that have built their supply chains and sales infrastructure within state-legal frameworks. This creates an arm's-length structure that allows institutional limited partners to gain exposure without direct involvement in federally prohibited activities.
Does Zion Ventures make direct investments in cannabis companies or only fund commitments?
Zion Ventures deploys capital through three channels: primary commitments to outside venture and growth equity funds, direct co-investments in mid-stage companies alongside those managers, and secondary purchases of existing limited partner interests. The direct allocation gives the firm the ability to overweight specific operators it encounters through its manager network, while secondaries provide a path to acquire stakes when original investors seek liquidity in a market with limited exit venues.
What investment stages does Zion Ventures target across its portfolio?
The firm covers the full spectrum from seed-stage startups to late-expansion companies. Seed investments typically focus on cultivation technology, genetics, and software platforms, while early-stage positions target branded products and retail infrastructure. Late-stage commitments back operators executing consolidation strategies across multiple state markets, often in advance of potential federal rescheduling or legalization that could enable interstate commerce.
Which sectors does Zion Ventures explicitly avoid?
Zion Ventures does not allocate to adult-use retail operators that lack a clear medical or therapeutic application, nor does it back businesses that operate in unregulated or illicit markets. The firm avoids pure-play cryptocurrency or blockchain cannabis ventures that combine two sectors with unsettled regulatory frameworks. It also does not invest in traditional agriculture or food-and-beverage companies outside the plant medicine mandate.
How does Zion Ventures source its underlying fund managers?
The firm's sourcing relies on a network cultivated across the cannabis venture and private equity ecosystem. Zion targets managers with operating experience in regulated state markets, particularly those who have built and exited cannabis businesses before transitioning to fund management. Because the cannabis investing community remains small and interconnected, deal flow often originates through relationships with portfolio company founders and legal counsel specializing in state-by-state licensing and compliance.
Is Zion Ventures structured as a single family office or an independent asset manager?
Zion Ventures operates as an independent fund-of-funds manager, not a single-family office. It was founded as a third-party asset management firm raising capital from institutional investors and high-net-worth individuals. The firm does not manage the wealth of a single family or founding principal, distinguishing it from the family-office cannabis investors that deploy proprietary capital directly into operating companies.
What is Zion Ventures' geographic focus?
Zion Ventures primarily invests in United States-based cannabis and hemp companies operating across state-legal markets, including California, Colorado, Michigan, Massachusetts, and emerging Mid-Atlantic and Northeastern jurisdictions. The firm also evaluates fund managers and direct opportunities in Canada and Europe, where federally legal medical and adult-use frameworks have created mature ecosystems for plant medicine companies that may eventually expand into the US market upon regulatory change.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: